Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.
Drug induced myopathy has been reported with the use of fibric acid derivatives, hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and nicotinic acid. Over the last three decades, hypolipemiants like fibric acid derivatives and statins have been increasingly recognised as causes of rhabdomyolysis and acute renal failure especially during combination therapy and in the presence of underlying renal impairment. We report two cases of bezafibrate-induced rhabdomyolysis in patients with underlying coronary artery disease and pre-existing renal impairment. Both patients developed rhabdomyolysis leading to acute renal failure soon after their hyperlipidaemia treatment was changed from gemfibrozil to bezafibrate. There were no intercurrent illnesses or co-administration of other lipid lowering drugs in both patients. Even though both drugs belong to the same fibric acid derivatives group, these patients developed the complication only after a switchover of therapy.
Kamaliah
M D
MD
Department of Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kelantan. kamalia@kb.usm.my
Sanjay
L D
LD
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000368:Aged; D001629:Bezafibrate / Q000009:adverse effects*; D003327:Coronary Disease / Q000150:complications; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D007674:Kidney Diseases / Q000150:complications; D008297:Male; D012206:Rhabdomyolysis / Q000139:chemically induced*
D000960:Hypolipidemic Agents; D015248:Gemfibrozil; D001629:Bezafibrate